The Brazilian Ministry of Health has confirmed 81 cases of mpox (monkeypox) across the country as of February 2026. While the majority of reported cases have been mild to moderate, with no fatalities recorded this year, health officials are maintaining vigilance and ongoing monitoring efforts. This follows a more significant outbreak in 2025, which saw 1,079 cases and two deaths attributed to the virus. The current situation underscores the continued, though diminished, presence of mpox globally and the importance of public health preparedness.
The majority of the confirmed cases in 2026 are concentrated in the state of São Paulo, accounting for 57 infections. Other affected states include Rio de Janeiro (13 cases), Rondônia (4), Minas Gerais (3), Rio Grande do Sul (2), and single cases reported in the Distrito Federal and Paraná. These regional concentrations are informing targeted public health responses and resource allocation. The Ministry of Health is collaborating closely with state epidemiological surveillance agencies to track the spread of the virus and implement effective control measures.
Mpox, caused by the MPXV virus – part of the Orthopoxvirus family – can affect individuals of any age. The initial symptoms often mimic those of other viral infections, including fever, headache, and muscle aches. However, a defining characteristic of mpox is the subsequent development of skin lesions, which can manifest as blisters, sores, or crusts. Early recognition of these symptoms is crucial for prompt diagnosis and management, and to limit further transmission.
Understanding Mpox: Transmission, Symptoms, and Prevention
Mpox is not a novel disease, having been first identified in humans in 1970 in the Democratic Republic of the Congo. The World Health Organization (WHO) provides comprehensive information on the virus, its transmission, and global outbreak updates. Transmission typically occurs through close contact with lesions, body fluids, respiratory droplets, and contaminated materials, such as bedding. While historically more prevalent in Central and West Africa, mpox has experienced outbreaks in other regions, including Europe and North America, in recent years.
The symptoms of mpox typically appear 5-21 days after exposure. Beyond the initial flu-like symptoms and characteristic skin lesions, individuals may also experience swollen lymph nodes (lymphadenopathy), particularly in the neck, armpits, or groin. The illness usually resolves within 2-4 weeks, but severe complications can occur, especially in individuals with weakened immune systems. It’s significant to note that the clinical presentation of mpox can vary, sometimes resembling other skin conditions, leading to potential misdiagnosis.
Brazil’s Public Health Response and Preparedness
The Brazilian Unified Health System (SUS) is playing a central role in responding to the current mpox situation. According to the Ministry of Health, the SUS is equipped for early identification, clinical management, and follow-up care for patients. The Ministry of Health emphasizes that surveillance teams are actively monitoring and investigating cases, with contact tracing conducted for 14 days – a measure considered essential for interrupting potential chains of transmission. This proactive approach aims to contain outbreaks and prevent widespread infection.
Contact tracing involves identifying individuals who may have been exposed to the virus and monitoring them for symptoms. Individuals identified as contacts are advised to self-isolate and seek medical attention if they develop any signs of illness. The Ministry of Health also recommends that individuals experiencing symptoms such as skin rashes, fever, and swollen lymph nodes seek medical evaluation promptly and inform healthcare providers of any potential exposure to mpox.
the Ministry of Health is reinforcing the importance of hygiene practices, such as frequent handwashing, to reduce the risk of transmission. Isolation, when possible, is also recommended until a medical evaluation can be completed. These measures align with international guidelines for mpox control, and prevention.
Vaccination and Treatment Options
While there is no specific treatment for mpox, supportive care is provided to manage symptoms and prevent complications. Antiviral medications developed for other orthopoxviruses, such as smallpox, may be used in severe cases. Vaccination is a key preventative measure, and several vaccines have been approved for use against mpox, including the JYNNEOS vaccine. The Centers for Disease Control and Prevention (CDC) provides detailed information on mpox vaccination strategies.
In Brazil, access to vaccination is being prioritized for individuals at higher risk of exposure, including healthcare workers and close contacts of confirmed cases. The Ministry of Health is working to ensure equitable access to vaccines across the country, particularly in regions with higher case counts. Ongoing research is also focused on evaluating the effectiveness of different vaccination strategies and developing new therapeutic options.
Looking Ahead: Continued Vigilance and Global Collaboration
The 81 confirmed cases of mpox in Brazil in 2026 represent a decrease from the 1,079 cases reported in 2025, but health officials caution against complacency. Continued surveillance, rapid diagnosis, and effective contact tracing remain crucial for controlling the spread of the virus. The Ministry of Health is committed to maintaining a robust public health response and collaborating with international partners to share information and best practices.
The global mpox outbreak has highlighted the importance of strengthening public health infrastructure and investing in research and development of vaccines and treatments for emerging infectious diseases. International collaboration is essential for preventing and responding to future outbreaks, and for ensuring equitable access to healthcare resources for all populations. The ongoing monitoring of mpox cases in Brazil, and around the world, will be critical for informing public health strategies and protecting communities from this evolving threat.
The next official update from the Brazilian Ministry of Health regarding mpox case numbers and vaccination efforts is scheduled for March 15, 2026. Stay informed by visiting the Ministry’s website and consulting with your healthcare provider if you have any concerns about mpox. Share this information with your network to help raise awareness and promote public health safety.
Keep reading